Neurodegenerative diseases can be broadly classified into familial (genetic) and sporadic (idiopathic) forms. While both share similar pathological features, understanding their distinctions is crucial for research, genetic counseling, and therapeutic development.
flowchart TD
subgraph Familial_Neurodegeneration
F1["Autosomal Dominant Genes"] --> F2["PSEN1/APP/PSEN2"]
F1 --> F3["SNCA/LRRK2/PARKIN"]
F1 --> F4["C9orf72/TARDBP/SOD1"]
F2 --> F5["Increased Protein Aggregation"]
F3 --> F5
F4 --> F5
F5 --> F6["Early Onset<br/>>95% penetrance"]
end
subgraph Sporadic_Nurodegeneration
S1["Risk Genes"] --> S2["APOE/TREM2"]
S2 --> S3["Polygenic Risk"]
S3 --> S4["Impaired Clearance"]
S4 --> S5["Age-Related<br/>Incomplete penetrance"]
end
F6 -->|"Shared"| B["Neurodegeneration"]
S5 -->|"Shared"| B
B --> B1["Mitochondrial Dysfunction"]
B --> B2["Neuroinflammation"]
B --> B3["Synaptic Loss"]
B --> B4["Cell Death"]
| Feature |
Familial Neurodegeneration |
Sporadic Neurodegeneration |
| Proportion |
~5-10% of cases |
~90-95% of cases |
| Inheritance |
Autosomal dominant/recessive |
Non-Mendelian |
| Age of Onset |
Typically earlier |
Typically later |
| Penetrance |
High (often >95%) |
Variable/incomplete |
| Known Causative Genes |
Yes |
Mostly risk factors |
Prevalence: <5% of all AD cases
Causative Genes:
- PSEN1 (chromosome 14) - 50-70% of FAD
- APP (chromosome 21) - 10-15% of FAD
- PSEN2 (chromosome 1) - <5% of FAD
Characteristics:
- Age of onset: Typically 30-60 years
- Penetrance: Virtually complete (>99%)
- Inheritance: Autosomal dominant
- Mechanism: Increased Aβ42 production/aggregation
Prevalence: >95% of all AD cases
Risk Genes:
Characteristics:
- Age of onset: Typically >65 years
- Penetrance: Incomplete (~40-50% by age 85)
- Inheritance: Polygenic, complex
| Feature |
Familial AD |
Sporadic AD |
| Proportion |
<5% |
>95% |
| Onset Age |
30-60 years |
>65 years |
| Primary Genes |
PSEN1, APP, PSEN2 |
APOE, TREM2, polygenic |
| Mechanism |
Increased Aβ42 production |
Impaired Aβ clearance |
| Penetrance |
>99% |
~40-50% |
| Family History |
Strong (autosomal dominant) |
Variable |
Prevalence: 5-10% of PD cases
Causative Genes (Autosomal Dominant):
- SNCA - A53T, A30P, E46K mutations
- LRRK2 - G2019S (most common)
- VPS35 - D620N
Causative Genes (Autosomal Recessive):
Prevalence: 90-95% of PD cases
Risk Genes:
- GBA variants (strongest risk)
- SNCA risk alleles
- LRRK2 risk variants
| Feature |
Familial PD |
Sporadic PD |
| Proportion |
5-10% |
90-95% |
| Onset Age |
Younger (40-60 years) |
Older (60-80 years) |
| Primary Genes |
SNCA, LRRK2, Parkin, PINK1 |
GBA, SNCA (risk) |
| Mechanism |
Protein aggregation, mitophagy defects |
Multi-factorial |
| Penetrance |
Variable (30-100%) |
Low |
| Family History |
Clear (dominant/recessive) |
Often absent |
Despite their genetic differences, both familial and sporadic forms converge on common pathological pathways:
¶ Protein Misfolding and Aggregation
- Familial: Direct mutations cause mutant protein aggregation
- Sporadic: Age-related proteostasis failure, post-translational modifications
- Familial: Direct mutations in mitochondrial proteins (PINK1, Parkin)
- Sporadic: Environmental toxins, age-related mtDNA damage
- Familial: TREM2 (AD), glial activation from protein aggregates
- Sporadic: Age-related microglial priming, chronic inflammation
- Familial: Mutations in autophagy genes
- Sporadic: Age-related lysosomal decline
| Disease |
Genes to Test |
Indication |
| AD |
PSEN1, PSEN2, APP (if early onset) |
Early onset, family history |
| AD |
APOE genotyping |
Risk assessment (limited) |
| PD |
LRRK2, SNCA, VPS35 |
Dominant family history |
| PD |
Parkin, PINK1, GBA |
Early onset, family history |
- Gene-specific therapies: Antisense oligonucleotides for specific mutations
- Mutation carriers: Eligible for prevention trials (DIAN, MAPT)
- Sporadic cases: Broader therapeutic approaches targeting shared mechanisms
- Sporadic disease mechanisms: Still poorly understood
- Gene-environment interactions: Limited data
- Modifier genes: How do genetic modifiers affect penetrance?
- Therapeutic translation: Most success in familial forms